To Cure Cancers
With Innovation and Speed

Committed to fight cancers with cutting-edge technologies
and innovative combination therapies, driven by a passionate team
hero-image-arrow Created with Sketch.

Our Pipeline

We are targeting multiple mechanisms to fight cancer with
single agent and combination Therapies
Training the immune
system to recognize cancers
Cancer Vaccines
Expanding and
mobilizing immune cells
Priming Agents
CTLA-4, CD137
Accelerating immune attack,
blocking immune resistance
Immune Checkpoints
PD-1, CTLA-4, CD137,
TIGIT, LAG-3, TIM-3,
etc...
Creating Inroads,
removing barriers
Tumor Microenvironment Conditioners
Bispecifics
(undisclosed)

Our Innovation Engine

We have state-of-the-art technology and manufacturing
platforms to repeatedly innovate with speed
Antibody Discovery and Development
In-house capabilities from early discovery to GMP manufacturing
Vaccine Technology
Innovative and highly differentiated “personalized” and “off-the-shelf” vaccines
Adaptive Learning Platform Systems (ALPS)
Artificial Intelligence (AI) based R&D platform to expand new molecular targets for cancer therapy
GMP Manufacturing Facility
(Berkeley, CA and Lexington, MA)
A key driver of rapid development that helps us advance faster than our peers
Cell Line Development Facility
(Cambridge, UK)
Key to execute rapid drug development

Publications, Presentations
& Other Stories

Scientific Conference
Presentations
Journal
Publications
Investor
Presentations

In The News

Our announcements regarding key data, regulatory
and business milestones and events
Recent
14 March 2019
Agenus Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
Read more >
13 March 2019
Agenus Milestone Triggers $7.5M Payment from Gilead
Read more >